印度基金 IFN 深滬

等待開盤 08-21 09:30:00 美东时间

15.85

+0.100

+0.63%

華盛通

立即下載

最高15.88
今開15.82
成交量 15.40万股
最低 15.789
昨收 15.75
總市值 6.24亿
52周最高 17.91
市盈率 ^靜 5.00
換手率 0.39%
52周最低 13.35
委比 93.86%
總股本 3935.67万
歷史最高 18.7795
量比 1.17
振幅 0.58%
歷史最低 -1.0016
每手 1
風險率 0.89%

個股概要

財務分析

公司資料

分紅派息

分時圖
日k
周k
月k

相關新聞

阿斯利康系统性红斑狼疮新药在国内申报上市

经济观察网8月20日，国家药品监督管理局（NMPA）药品审评中心（CDE）官网显示，阿斯利康的阿伏利尤单抗注射液上市申请已获受理，用于治疗系统性红斑...

08-20 15:51
国金医药甘坛焕丨创新药前瞻深度：从IL-2双抗，看TAA、细胞及趋化因子的PD-1升级新方向

（来源：国金证券研究所）　　作者：甘坛焕、赵海春摘要背景创新药BD（授权合作交易）及其首付额爆发，下一个十亿美元首付花落谁家成市场新焦点。（...

08-14 07:34
India Fund declares $0.43 dividend

India Fund (NYSE:IFN) declares $0.43/share monthly dividend. Payable Sept. 30; for shareholders of record Aug. 22; ex-div Aug. 22. See IFN Dividend Scorecard, Yield Chart, & Dividend Growth. More on I...

08-13 00:45
【天风医药杨松团队|首次覆盖】石药集团：创新管线步入兑现期，海外授权彰显平台价值

（来源：一棵大松树）授权收入+新增品种有望带来业绩增量，八大平台彰显研发实力石药集团是一家集研发、生产和销售于一体创新制药企业，成药业务为第...

08-12 15:14
TSLP：自免领域崛起的“吸金”明星靶点

（来源：药研网）前言 2025年上半年，阿斯利康财报显示其呼吸与免疫领域重磅产品Tezspire（TSLP单抗）销售额同比增长高达73%，推动公司整体业绩增长...

08-12 07:55
ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS

PHILADELPHIA, Aug. 11, 2025 /PRNewswire/ -- The following Aberdeen Investments U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, THQ, THW and NYSE American: FAX, FCO, IAF...

08-12 04:17
Sonnet Biotherapeutics Announces Expansion Of Its Phase 1b/2a Clinical Study Evaluating The Combination Of SON-1010 With Genentech's Atezolizumab In Patients With Platinum-Resistant Ovarian Cancer

Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221)Topline safety, cytokine, and

08-04 20:43
Alumis Completes Patient Enrollment In Global LUMUS Phase 2b Trial Of ESK-001, Next-Gen Oral Tyrosine Kinase 2 Inhibitor, For Treatment Of SLE; Topline Readout Expected In Q3 2026

Alumis Inc. (NASDAQ:ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient enrollment in its global

07-24 19:35
多面手OX40：炎症、自免、肿瘤治疗新希望

（来源：药研网）前言 2025年7月2日，创响生物宣布，抗OX40单抗IMG-007在中重度特应性皮炎（AD）国际多中心IIb期研究（ADAPTIVE，NC...

07-23 07:50
安科生物:公司与阿法纳公司共同研发的治疗HPV肿瘤和癌前病变的AFN0328注射...

有投资者在深交所互动平台向安科生物提问："请问，公司在研的新药有几种？公司每年新药研发投入大概多少？"公司回复称："您好，公司进入临床阶段的研发管线如下：一、抗...

07-22 17:23

派息除權日	每股總股息	派息日期
2025-08-22	0.43	2025-09-30
2025-05-22	0.41	2025-06-30
2025-02-21	0.46	2025-03-31
2024-11-21	0.93	2025-01-10
2024-08-23	0.49	2024-09-30
2024-05-30	0.45	2024-07-05
2024-02-21	0.43	2024-03-28
2023-11-21	0.41	2024-01-10
2023-08-23	0.41	2023-09-29
2023-05-18	0.39	2023-06-30
2023-02-17	0.43	2023-03-31
2022-11-21	1.61	2023-01-11
2022-08-23	0.46	2022-09-30
2022-05-19	0.53	2022-06-30
2022-03-23	0.58	2022-03-31
2021-12-29	0.64	2022-01-11
2021-12-17	0.80	2022-01-31
2021-09-17	0.61	2021-09-30
2021-06-22	0.58	2021-06-30
2021-03-23	0.58	2021-03-31
2020-12-18	0.50	2020-12-30
2020-09-18	0.46	2020-09-30
2020-06-18	0.42	2020-06-30
2020-03-19	0.57	2020-03-31
2019-12-30	0.57	2020-01-10
2019-09-20	0.58	2019-09-30
2019-06-20	0.59	2019-06-28
2019-03-20	0.59	2019-03-29
2018-12-28	2.32	2019-01-10
2018-09-21	0.71	2018-10-02
2018-06-20	0.71	2018-06-29
2018-04-19	0.76	2018-04-27
2017-12-28	2.83	2018-01-08
2017-09-21	0.33	2017-09-29
2016-12-28	1.49	2017-01-11
2016-09-19	0.22	2016-09-28
2015-12-29	1.43	2016-01-12
2015-09-17	0.40	2015-09-28
2014-12-29	1.74	2015-01-12
2014-09-18	0.13	2014-09-30
2013-12-27	0.89	2014-01-17
2013-10-01	0.06	2013-10-18
2012-12-19	2.37	2013-01-31
2011-12-28	0.32	2012-01-13
2011-09-29	0.88	2011-10-14
2010-12-29	3.78	2011-01-14
2010-09-29	0.09	2010-10-15
2008-12-29	0.67	2009-01-15
2008-10-07	6.45	2008-10-23
2007-12-27	8.18	2008-01-14
2007-10-02	1.43	2007-10-18
2006-12-27	3.46	2007-01-12
2006-10-02	0.59	2006-10-18
2006-04-12	1.07	2006-04-20
2005-12-28	4.46	2006-01-12
2004-12-29	1.52	2005-01-14
2003-12-26	0.13	2004-01-09
2002-12-27	0.09	2003-01-10
2001-12-19	0.07	2002-01-11
1996-12-24	0.010	1997-01-10
1994-12-23	0.13	1995-01-13

公司名稱	印度基金
行業分類	资产管理
業務描述	The India Fund, Inc. (the Fund) is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing primarily in the equity securities of Indian companies. The Fund's portfolio of investments includes financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities and others. The Fund's investment manager is Aberdeen Asset Management Asia Limited (AAMAL). Aberdeen Asset Management Inc. (AAMI), an affiliate of AAMAL, serves as the Fund's administrator.

印度基金 IFN 深 滬

15.85

個股概要

財務分析

公司資料

相關新聞

分紅派息

相關新聞

公司簡介

印度基金 IFN 深滬